Advanced Health Limited Overview
Advanced Health is a privately held South African operator of independent, same-day surgical hospitals (day hospitals). It runs a network of nine facilities in Gauteng, Mpumalanga, the Western Cape and the Eastern Cape. Its proposition is cost: the company says its same-day procedures are priced up to 30% below the same procedure in larger acute hospitals [S35]. It also targets the medical schemes, including low-cost options, that increasingly steer elective short-stay surgery away from acute hospitals [S5]. From its 2014 AltX listing until 2023 the group was dual-market. The profitable PresMed Australia subsidiary financed a loss-making South African build-out that never reached group-level profitability attributable to shareholders. After selling Australia to an ICG-led consortium and delisting, the business is a single-country, founder-controlled platform. It competes against the day-surgery arms of Netcare, Life Healthcare and Mediclinic and against independent chains such as Cure Day Hospitals. In February 2026 it announced that it had become the first hospital group in Africa certified to ISO 7101 [S36].
Company's own description (latest available filings and website)
In its last published interim report (H1 FY2023), the company described itself as an important participant in day surgery in South Africa and Australia. It said it had positioned itself within each market's healthcare system to meet growing demand for day procedures [S5 · H1 FY2023]. The current website states the aim of being the industry leader in day surgery through a network of day hospitals, with a focus on high-quality, cost-effective care [S37 · 2026]. It defines day hospitals as facilities performing short surgical and diagnostic procedures in a sterile environment on a same-day basis, and claims that more than 60% of surgical interventions can be done this way [S37].
Independent characterisation
Advanced Health is a facility operator, not a clinical practice. Revenue comes from patients, almost entirely funded by medical schemes and partly by private cash payers. It is billed as facility, theatre and accommodation fees, equipment and fixed fees, and drugs and gases dispensed during procedures [S4 · FY2022]. Surgeons and anaesthetists are independent practitioners who bill separately. The model depends on three relationships:
-
Doctors. Surgeons choose where to operate. The group has historically offered participating doctors equity in each hospital's operating company while retaining majority control [S46]. The FY2022 and H1 FY2023 turnaround plans made selling shares in South African hospitals to specialists a formal strategic pillar [S4], [S5].
-
Funders (medical schemes). Volume depends on network inclusion and tariff levels. Advanced Health is a member of the Day Hospital Association of South Africa (DHASA), which was authorised to negotiate tariffs collectively with schemes for 2023 [S4], [S5].
-
Real estate. Facilities are mostly leased. On adopting IFRS 16 on 1 July 2019 the group recognised lease liabilities of R607.7m and right-of-use assets of R583.8m [S2 · FY2020]. This made lease finance costs the dominant fixed charge below EBITDA.
Business and revenue model mix
| Revenue line (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
| Theatre, accommodation and facility fees (ZAR m) | 360.7 | 407.3 | 392.0 | 574.3 | 555.0 |
| Equipment and fixed fees (ZAR m) | 6.6 | 18.8 | 21.4 | 12.8 | 13.9 |
| Specialists (ZAR m) | 0.0 | 0.0 | 0.0 | 0.0 | 11.4 |
| Drug revenue and gases (ZAR m) | 39.3 | 55.5 | 62.8 | 93.6 | 84.4 |
| Total revenue (ZAR m) | 406.6 | 481.7 | 476.2 | 680.7 | 664.7 |
Sources: [S1 · FY2019 (FY2018–19)], [S2 · FY2020], [S4 · FY2022 (FY2021–22)]. "Specialists" revenue came from the consolidated Metwest entities in Australia from November 2021 [S4].
In FY2022, 90% of drug revenue came from South Africa, while 77% of facility-fee revenue came from Australia [S4 · FY2022]. This shows a structural difference: the South African hospitals depend far more on pharmaceutical dispensing.
Value-chain position, customers and end-markets
Value-chain position: a provider-level facility operator between funders (medical schemes and private payers) and independent specialists. It does not run medical schemes, own physician practices (except Metwest's ophthalmology practice in Australia before 2023) or manufacture anything.
Customer types: (i) patients, funded mainly by medical schemes; the website shows Discovery, GEMS, Bonitas, Polmed and Fedhealth logos [S35]; (ii) private cash patients, for whom the group points to third-party medical-loan providers [S35]; (iii) specialists as the de facto "channel"; (iv) institutional overflow in 2021, when theatres were made available to 1 Military Hospital [S21].
End-markets: South African private elective short-stay surgery (current). Australian private day surgery, mainly ophthalmology, ENT, pain management and oral-maxillofacial surgery, until 2023 [S8].
Strategy
Stated strategy (latest filings, FY2022 and H1 FY2023; paraphrased)
The last published strategy framed the South African turnaround around four pillars [S4], [S5]:
-
Specialist partnership: selling equity in South African hospital operating companies to medical specialists.
-
Funder engagement: using DHASA's authorisation to negotiate tariffs collectively with medical schemes (2023 tariffs) to secure reasonable increases and channel more volume to member hospitals.
-
Marketing and doctor acquisition: engaging doctors, recruiting new specialists, and differentiating on service, including nursing care.
-
Competitive pricing: for both private and low-income medical-scheme options, positioned for members downgrading to cheaper plans. Advanced Health says it accepts most low-cost options [S5].
Post-delisting statements (2026). The managing director described three core strategic pillars aimed at benefiting staff, patients and doctors, under the theme of affordable, quality care [S36]. Quality certification (ISO 7101, with three years of surveillance audits) is the most visible initiative [S36].
Strategic initiatives register (last 24 months and recent history)
| Date | Initiative | Detail | Source |
|---|---|---|---|
| Not disclosed (website material from 2025) | MFT Gqeberha integration | Added the Eastern Cape's first private day hospital (3 theatres) to the network | [S39] |
| Late 2025 – 9 Feb 2026 | ISO 7101 healthcare quality management | BSI audits of all hospitals and the central office; certification announced Feb 2026; ongoing compliance audits over three years | [S36] |
| 2025–2026 | Patient-experience transparency | Per-hospital patient-feedback scores published on the website (updated Oct 2026) | [S35] |
| 2025–2026 | Consumer funding channel | Private-funding pathway via third-party lenders for procedures and shortfalls | [S35] |
| 2,023 | Delisting to cut compliance costs | Board said listing costs exceeded benefits; capital raising would be better served unlisted | [S11] |
| 2,023 | Balance-sheet restructuring | PMA proceeds used first to settle outstanding credit facilities and fund South African working capital | [S8], [S5] |
| 2,021 | Cost-curtailment restructuring | Closure of loss-making Soweto; sale of Vergelegen; strict South African cost measures | [S18] |
Medium-term targets and guidance
Not publicly disclosed. The company has never published quantitative medium-term financial targets. The last stated objective was qualitative: to become profitable and grow the footprint of independent, quality, cost-effective day hospitals [S5].
Sustainability and ESG commitments
Not publicly disclosed.
Products & Services
Service lines (billing categories)
| Service line | Description | Target customer | Pricing model | Source |
|---|---|---|---|---|
| Theatre / accommodation / facility fees | Use of theatre, recovery and ward for same-day procedures | Scheme-funded and cash patients | Negotiated scheme tariffs; co-payments per scheme rules; possible co-payment discounts for cash patients | [S4], [S35] |
| Equipment and fixed fees | Equipment use and fixed procedural charges (includes dental income and fee adjustments per FY2019 note) | As above | Per procedure | [S1], [S4] |
| Drugs and gases | Pharmaceuticals and medical gases used in procedures | As above | Per item dispensed | [S4] |
| Specialist services (Australia only, FY2022) | Ophthalmology practice revenue at Metwest | Australian private patients | Practice fees | [S4] |
| Private funding facilitation | Referral to third-party medical-finance providers for procedures, co-payments and shortfalls | Uninsured or under-insured patients | Third-party loan; terms not disclosed | [S35] |
| Central-office management services | Management services provided to Summerhill Surgical Centre (third-party day hospital) | Independent facility | — | [S38] |
Clinical specialties offered (group level)
The company's descriptions and third-party profiles list: orthopaedics (knee, shoulder, elbow, hand, spine) including same-day hip and knee replacement (more than 300 performed); ophthalmology (cataract, corneal, laser, intra-ocular injection, vitrectomy, tear duct, pterygium; oculoplastics featured in 2026 content); ENT; gynaecology; urology; plastic, reconstructive and cosmetic surgery; dermatological excisions; dental and maxillofacial surgery; general surgery; and diagnostic endoscopy and colonoscopy [S35], [S37], [S49], [S36]. PMA in Australia specialised in ophthalmology, ENT, pain management and oral-maxillofacial surgery [S8].
Facility catalog — South Africa (current, per website, October 2026)
| Facility | Location | Province | Key specifications | Opening / joining | Source |
|---|---|---|---|---|---|
| Advanced De La Vie | Beatty Ave, Witbank (eMalahleni) | Mpumalanga | Not disclosed. The De La Vie CGU's goodwill (R4.7m) was fully impaired in FY2020. The site appears linked to the former Witbank Day Clinic / Emalahleni Day Hospital, but the company has not confirmed this | Emalahleni reopened 2009; De La Vie date not disclosed | [S35], [S2], [S37] |
| Advanced Durbanville | 3 Somerset Crescent, Durbanville, Cape Town | Western Cape | — | Planned for Q3 2015 (pre-opening guidance) | [S35], [S46] |
| Advanced East Rand | 52 Olivia Rd, Eveleigh, Boksburg | Gauteng | Not disclosed. Classified within a held-for-sale group in FY2020 but still operating | — | [S35], [S2] |
| Advanced Harbour Bay | Main and Dido Valley Rd, Simon's Town | Western Cape | Capex R8.3m in FY2020 | Opened 17 January 2020 | [S35], [S2] |
| Advanced Knysna | 4 Barracuda St, Fisher Haven, Knysna | Western Cape | Not disclosed; deferred tax asset derecognised FY2020 | — | [S35], [S2] |
| Advanced MFT (Medical Forum Theatre) | 209 Cape Road, Mill Park, Gqeberha | Eastern Cape | 3 theatres, 15 beds, 7 ophthalmic recliner chairs; described as the Eastern Cape's first private day hospital | Joined post-delisting; date and terms not disclosed | [S39] |
| Advanced Medgate | Kingfisher and Pheasant St, Helderkruin, Roodepoort | Gauteng | — | One of two South African facilities at the 2014 listing | [S35], [S27] |
| Advanced Panorama | 55 Hennie Winterbach St, Panorama, Cape Town | Western Cape | — | Operational January 2016 | [S35], [S25] |
| Advanced Worcester | 43 Russell St, Worcester | Western Cape | — | — | [S35] |
Former South African facilities: Advanced Vergelegen Surgical Centre (Somerset West; business sold to Hibosys / Summerhill Surgical Centre in 2021) [S18]; Advanced Soweto Day Hospital (operations discontinued 2021; liquidated 11 August 2022) [S4].
Facility catalog — Australia (divested 2023)
| Facility | Location | Notes | Source |
|---|---|---|---|
| Chatswood Private Hospital | Chatswood, Sydney | Flagship six-theatre day clinic opened January 2016; only Australian private hospital member of the World Association of Eye Hospitals | [S25], [S1], [S4] |
| Epping Surgery Centre | Epping, Sydney | New lease in FY2022 added R60.3m of right-of-use assets | [S4] |
| Central Coast facility | Central Coast, NSW | Named facility not disclosed in the filings retrieved | [S33] |
| Hornsby facility | Hornsby, Sydney | One-theatre ophthalmic day hospital acquisition agreed in principle (2017) | [S24], [S33] |
| Metwest Surgical (Hereward) and Eye Centre (Kingham) | Blacktown / Western Sydney | 19% (2019), later 38% (associate), then 57% (Nov 2021, controlled) | [S1], [S4], [S33] |
| Devonport Eye Hospital and Clearvis (DEVOCLEA) | Devonport, Tasmania | 20% (July 2021), later 40% associate | [S22], [S4] |
| Sydney Pain Day Surgery | Sydney | Right-of-use asset of R12.5m recognised in H1 FY2023 | [S5] |
| Madison Day Surgery | Sydney (location not disclosed) | 100% acquired in FY2018 | [S1] |
| Coffs Harbour Day Hospital | Coffs Harbour, NSW | One-theatre clinic; closed and sold 29 March 2019 | [S1] |
PMA owned or co-owned ten operating facilities (day hospitals and consultation clinics) at the time of sale [S8].
Flagship differentiators claimed
-
Price: up to 30% cheaper than the same procedure at larger hospitals (company claim) [S35].
-
Quality: ISO 7101 certification across all hospitals and the central office, awarded by BSI and announced 9 February 2026 [S36].
-
Patient satisfaction: the website displays an average score of 97% or above from patient feedback [S35].
-
Australian training credentials (pre-2023): an in-house ophthalmic nurse programme, an ophthalmologist registrar training programme and University of Sydney teaching-hospital affiliation [S4].
Financial Narrative
Coverage: FY2018–FY2022 audited or reviewed annual figures. FY2023 annual results were not publicly disclosed; no FY2023 annual filing was located before the September 2023 delisting. FY2018 and FY2019 are pre-IFRS 16 and FY2020 onward are post-IFRS 16, so EBITDA, finance costs and debt are not like-for-like across that break.
Income statement
Sources: [S1 · FY2019 (FY2018–19)], [S2 · FY2020], [S4 · FY2022 (FY2021–22)]. Notes: FY2019 cost of sales and gross profit are as restated in FY2020 after the nursing-cost reclassification. FY2018 gross profit (R207.3m) is as originally presented and is not adjusted for that reclassification, so it is not strictly comparable. EBIT is analyst-derived as EBITDA − D&A − impairments, excluding investment income, associate income and fair-value gains. FY2022 pre-tax income includes a R17.7m Metwest fair-value gain and R9.4m of associate income. FY2021 attributable figures are as restated in FY2022.
Sources: [S1], [S2], [S4]. FY2021 EPS as restated in FY2022 (originally −5.21c basic and −3.89c headline) [S4]. A 20c clean-out dividend per share was paid on 27 September 2023 (FY2024), declared out of income reserves [S14], [S17].
Analyst-derived. Revenue CAGR FY2018–FY2022: 13.1% (R406.6m to R664.7m). In AUD-neutral terms Australian revenue grew from about AUD29.0m to AUD40.4m. Part of the FY2021 ZAR jump came from a weaker rand (average AUD/ZAR 11.49 in FY2021 against 10.49 in FY2020) [S2], [S4].
Income statement commentary.
FY2018–FY2019 (build-out drag): Revenue rose 18% in FY2019 on 21% more cases, with South Africa up 38% [S1]. Losses persisted because the eight South African hospitals commissioned in a short period took longer than expected to settle in. Management itself guided that new hospitals need a "settling-in period" of up to 36 months [S25], [S1].
FY2020 (IFRS 16 and COVID): Reported EBITDA tripled to R54.5m, but R46.6m of that was the IFRS 16 reclassification of rent. Excluding IFRS 16, EBITDA fell 55% to R7.9m because of the Q4 lockdown [S2]. The net loss reached R133.8m, driven by IFRS 16 interest (R51.4m), the derecognition of R21.6m of South African deferred tax assets and the De La Vie goodwill impairment [S2].
FY2021 (post-lockdown backlog): Revenue jumped 43% to R680.7m. Australia's EBITDA was R133.6m as deferred elective surgery flowed back, a surge the company later called non-recurring [S4]. The group made a small after-tax profit of R0.6m, but owners still lost R27.7m.
FY2022 (normalisation): Revenue eased 2% and EBITDA fell to R134.3m. Australia was hit by Delta- and Omicron-era throughput caps, and South Africa by lower revenue and load-shedding costs [S4]. Profit after tax of R13.4m relied on the R17.7m non-cash Metwest gain. Without it, the group would have reported a loss.
Balance sheet
Sources: [S1], [S2], [S4]; derived totals are analyst-derived. Lease liabilities for FY2018–FY2019 are finance-lease obligations only (pre-IFRS 16; operating-lease straight-lining liabilities of R24.5m and R28.1m are excluded). FY2020 total assets include R202.7m of disposal-group assets. FY2021 equity split is restated. Working capital includes disposal groups.
Balance-sheet commentary. Three features stand out. (1) IFRS 16 doubled the balance sheet in FY2020: lease liabilities went from R20.9m to R467.7m, which permanently raised reported leverage. (2) Attributable equity collapsed from R193.8m (FY2018) to R19.0m (FY2022) as accumulated losses reached R294.8m [S4], while NCI grew to R214.2m. Minorities therefore owned most of the book equity, mainly through PMA. (3) The book value understated the economic value of PMA. AVL's 56.44% stake was sold for about R522m [S8], against total group attributable equity of R19.0m at 30 June 2022. This gap underpins the board's statement that the shares traded at a discount to underlying net asset value [S11].
Cash flow
Sources: [S1], [S2], [S4]; FCF analyst-derived.
Source: [S4 · FY2022]; FCF after leases analyst-derived. For FY2020 the cash-flow statement combines lease interest with other finance costs (R41.5m) alongside R17.5m of lease capital repaid [S2], so a like-for-like figure cannot be isolated.
Cash-flow commentary. Under IFRS 16 rent moves into financing, so the improvement in operating cash flow from FY2020 is mostly presentational. On a lease-adjusted basis, group FCF was modest: about R27m in FY2021 and R23m in FY2022. That was smaller than dividends paid out to Australian minorities in FY2022 (R18.6m) plus South Africa's financing needs. Eenhede Konsultante filled the gap: R53.8m of new loans in FY2022 and R6.2m in H1 FY2023 [S4], [S5]. The cash-flow statements show no capital returned to AVL shareholders until the 2023 clean-out dividend.
Ratios
All analyst-derived from [S1], [S2], [S4]. ROIC assumes the 28% South African statutory rate. Working-capital days use closing balances, and payables include non-trade items, so the cycle is approximate. FY2021 DSO is inflated by a R15.2m Devonport deposit held in receivables [S4]. Company-reported current ratios, which exclude disposal groups, were 1.02 (FY2019), 0.80 (FY2020), 1.20 (FY2021) and 1.27 (FY2022) [S1], [S2], [S4]. The analyst figure for FY2022 (1.22) does not reconcile exactly to the company's 1.27.
Analyst-derived; FY2018 is not meaningful because EBITDA was negative.
Ratio commentary. Attributable ROE was deeply negative throughout. The FY2020 and FY2022 figures look extreme because attributable equity had shrunk to a very small base. The more informative signal is EBIT interest cover of 1.1–1.3x in the two best years (FY2021–FY2022), meaning almost all operating profit went to lenders and lessors before reaching any shareholder. The structurally negative cash conversion cycle (payables longer than receivables plus inventory) is typical of hospitals. In FY2022 the company also said South African trade creditors were rising because of cash-flow strain [S4], which suggests creditors were partly financing the business.
Going-concern history
Auditors Mazars issued unmodified review opinions with emphasis-of-matter paragraphs on going concern in FY2020 and FY2022 [S2], [S4]. Third-party coverage also reported auditor doubts [S9a]. In FY2022, South Africa's current liabilities exceeded its current assets by R40.9m [S4]. The board's stated mitigation was the sale of strategic investments, which became the PMA disposal [S4], [S8].
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Services |
|---|---|---|
South Africa | Advanced Health South Africa (Pty) Ltd and its hospital operating companies (doctor co-owned) | Day-surgery facility fees, equipment fees, drugs and gases |
Australia (to 2023) | PresMed Australia Pty Ltd and subsidiaries/associates: Chatswood Private Hospital, Epping Surgery Centre, Central Coast, Hornsby, Metwest (Blacktown / Western Sydney), Devonport (Tasmania, 40% associate), Sydney Pain Day Surgery, among others | Day-surgery facility fees; specialist ophthalmology consulting (Metwest) |
Corporate | Advanced Health Limited (listed company) | Holding-company costs; borrowings from Eenhede Konsultante |
Segment revenue (ZAR Mn)
| Segment revenue (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
South Africa (ZAR Mn) | 117.4 | 162.2 | 177.0 | 229.5 | 219.1 |
Australia (ZAR Mn) | 289.2 | 319.4 | 299.3 | 451.2 | 445.7 |
Group (ZAR Mn) | 406.6 | 481.7 | 476.2 | 680.7 | 664.7 |
Segment revenue growth YoY (%)
| Segment revenue growth YoY (%) | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
South Africa (%) | 38.2 | 9.1 | 29.7 | -4.6 |
Australia (%) | 10.5 | -6.3 | 50.8 | -1.2 |
Group (%) | 18.5 | -1.1 | 42.9 | -2.3 |
Revenue contribution (% of group)
| Revenue contribution (% of group) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
South Africa (%) | 28.9 | 33.7 | 37.2 | 33.7 | 33.0 |
Australia (%) | 71.1 | 66.3 | 62.8 | 66.3 | 67.0 |
Segment profit/(loss) after tax (ZAR Mn)
| Segment profit/(loss) after tax (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
South Africa (ZAR Mn) | -42.8 | -46.0 | -132.4 | -47.7 | -41.0 |
Australia (ZAR Mn) | 7.5 | 9.9 | 14.4 | 62.5 | 62.6 |
Corporate (ZAR Mn) | -1.0 | -1.9 | -15.8 | -14.3 | -8.2 |
Group (ZAR Mn) | -36.2 | -38.0 | -133.8 | 0.6 | 13.4 |
Segment EBITDA (ZAR Mn)
| Segment EBITDA (ZAR Mn) | FY2021 | FY2022 |
|---|---|---|
South Africa (ZAR Mn) | 37.3 | 27.4 |
Australia (ZAR Mn) | 133.6 | 108.0 |
Corporate (ZAR Mn) | -8.3 | -1.0 |
Segment EBITDA margin (%)
| Segment EBITDA margin (%) | FY2021 | FY2022 |
|---|---|---|
South Africa (%) | 16.3 | 12.5 |
Australia (%) | 29.6 | 24.2 |
Results by Segment
| Item (ZAR Mn) | H1 FY2022 | H1 FY2023 |
|---|---|---|
Continuing revenue (South Africa) | 103.9 | 126.6 |
Continuing gross profit | 45.3 | 59.8 |
Continuing EBITDA (incl. corporate) | 11.9 | 13.7 |
South Africa segment EBITDA | 15.1 | 17.3 |
Continuing finance costs | 19.7 | 22.2 |
Loss from continuing operations | -21.9 | -23.1 |
Profit from discontinued operations (Australia) | 22.7 | 23.6 |
Group profit after tax | 0.8 | 0.4 |
Income statement (ZAR Mn)
| Income statement (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Revenue (ZAR Mn) | 406.6 | 481.7 | 476.2 | 680.7 | 664.7 |
Cost of sales (ZAR Mn) | 199.3 | 255.8 | 261.6 | 348.4 | 344.9 |
Gross profit (ZAR Mn) | 207.3 | 225.9 | 214.6 | 332.3 | 319.8 |
EBITDA as reported (ZAR Mn) | -0.1 | 17.6 | 54.5 | 162.6 | 134.3 |
Depreciation and amortisation (ZAR Mn) | 32.5 | 34.5 | 71.5 | 66.8 | 71.6 |
Impairments (ZAR Mn) | 0.0 | 0.0 | 4.7 | 9.9 | 4.8 |
Operating income, EBIT derived (ZAR Mn) | -32.6 | -16.9 | -21.7 | 85.9 | 57.9 |
Finance costs (ZAR Mn) | 14.7 | 16.4 | 74.2 | 67.5 | 53.8 |
Pre-tax income, continuing (ZAR Mn) | -46.5 | -32.4 | -94.1 | 24.4 | 31.6 |
Tax charge, negative = credit (ZAR Mn) | -15.8 | -7.8 | 39.7 | 23.8 | 18.1 |
Net income, total group (ZAR Mn) | -36.2 | -38.0 | -133.8 | 0.6 | 13.4 |
Net income attributable to owners (ZAR Mn) | -39.6 | -44.7 | -147.1 | -27.7 | -20.1 |
Net income attributable to NCI (ZAR Mn) | 3.3 | 6.7 | 13.3 | 28.3 | 33.6 |
Per-share data (ZAR cents)
| Per-share data (ZAR cents) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Basic EPS, total (ZAR cents) | -14.12 | -15.51 | -51.08 | -8.14 | -4.04 |
Diluted EPS, total (ZAR cents) | -14.12 | -15.51 | -51.08 | -8.14 | -4.04 |
Headline EPS (ZAR cents) | -14.12 | -10.84 | -49.42 | -6.82 | -5.89 |
Dividend per share (ZAR cents) | 0 | 0 | 0 | 0 | 0 |
Weighted average shares (millions) | 280.4 | 288.0 | 288.0 | 340.5 | 498.8 |
Margins (%)
| Margins (%) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Gross margin (%) | 51.0 | 46.9 | 45.1 | 48.8 | 48.1 |
EBITDA margin (%) | 0.0 | 3.7 | 11.4 | 23.9 | 20.2 |
Operating (EBIT) margin (%) | -8.0 | -3.5 | -4.6 | 12.6 | 8.7 |
Net margin, total group (%) | -8.9 | -7.9 | -28.1 | 0.1 | 2.0 |
Net margin, attributable (%) | -9.7 | -9.3 | -30.9 | -4.1 | -3.0 |
Balance Sheet
| Balance sheet (ZAR Mn, 30 June) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Total assets (ZAR Mn) | 515.0 | 531.2 | 1,078.3 | 926.3 | 1,096.0 |
Cash and equivalents (ZAR Mn) | 41.3 | 45.2 | 59.8 | 107.2 | 129.7 |
Borrowings excl. leases (ZAR Mn) | 145.7 | 200.2 | 181.6 | 192.6 | 213.6 |
Lease liabilities (ZAR Mn) | 38.2 | 20.9 | 467.7 | 431.9 | 537.9 |
Bank overdraft (ZAR Mn) | 0.0 | 11.3 | 3.1 | 11.4 | 7.7 |
Total debt incl. leases (ZAR Mn) | 183.9 | 232.4 | 652.4 | 635.9 | 759.2 |
Short-term debt (ZAR Mn) | 36.9 | 42.4 | 64.4 | 74.9 | 77.0 |
Long-term debt (ZAR Mn) | 147.0 | 189.9 | 587.9 | 561.0 | 682.2 |
Net debt incl. leases (ZAR Mn) | 142.6 | 187.2 | 592.6 | 528.7 | 629.5 |
Net debt excl. leases (ZAR Mn) | 104.4 | 166.3 | 124.9 | 96.8 | 91.6 |
Equity attributable to owners (ZAR Mn) | 193.8 | 145.8 | 38.7 | 44.5 | 19.0 |
Non-controlling interest (ZAR Mn) | 53.5 | 64.1 | 115.6 | 135.2 | 214.2 |
Total equity (ZAR Mn) | 247.3 | 210.0 | 154.4 | 179.7 | 233.2 |
Goodwill and intangibles (ZAR Mn) | 63.7 | 60.4 | 48.8 | 37.8 | 107.3 |
Working capital, total CA − CL (ZAR Mn) | -0.9 | 1.8 | -21.5 | 30.0 | 39.1 |
Cash flow (ZAR Mn)
| Cash flow (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Cash generated from operations (ZAR Mn) | 5.8 | 15.6 | 77.6 | 111.8 | 140.1 |
Net operating cash flow (ZAR Mn) | -13.2 | -5.7 | 58.7 | 104.8 | 105.2 |
Capex, PPE and intangibles (ZAR Mn) | 55.8 | 17.5 | 18.7 | 12.3 | 25.0 |
Free cash flow, operating less capex (ZAR Mn) | -69.0 | -23.2 | 40.0 | 92.5 | 80.2 |
Dividends paid to NCI by subsidiaries (ZAR Mn) | 6.0 | 8.3 | 10.2 | 10.7 | 18.6 |
Dividends paid to AVL shareholders (ZAR Mn) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (ZAR Mn) | 0 | 0 | 0 | 0 | 0 |
Lease cash outflows, post-IFRS 16 (ZAR Mn)
| Lease cash outflows, post-IFRS 16 (ZAR Mn) | FY2021 | FY2022 |
|---|---|---|
Lease capital repayments (ZAR Mn) | 16.0 | 20.7 |
Lease interest paid (ZAR Mn) | 49.2 | 36.9 |
FCF after lease payments (ZAR Mn) | 27.3 | 22.6 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratios | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
ROE, attributable earnings / closing attributable equity (%) | -20.4 | -30.6 | -380.1 | -62.2 | -105.8 |
ROE, total profit / closing total equity (%) | -14.7 | -18.1 | -86.7 | 0.3 | 5.8 |
ROA, total profit / closing total assets (%) | -7.0 | -7.2 | -12.4 | 0.1 | 1.2 |
ROIC, EBIT × (1 − 28%) / (equity + net debt incl. leases) (%) | -6.0 | -3.1 | -2.1 | 8.7 | 4.8 |
Current ratio, analyst incl. disposal groups (x) | 0.99 | 1.02 | 0.94 | 1.16 | 1.22 |
Debt / equity, incl. leases (x) | 0.74 | 1.11 | 4.23 | 3.54 | 3.26 |
Interest coverage, EBIT / finance costs (x) | -2.22 | -1.03 | -0.29 | 1.27 | 1.08 |
EBITDA / finance costs (x) | -0.01 | 1.07 | 0.73 | 2.41 | 2.50 |
Asset turnover, revenue / closing total assets (x) | 0.79 | 0.91 | 0.44 | 0.73 | 0.61 |
Days sales outstanding (days) | 30.0 | 28.6 | 26.7 | 37.1 | 30.0 |
Days inventory outstanding (days) | 25.6 | 23.0 | 21.2 | 20.0 | 21.7 |
Days payables outstanding (days) | 84.1 | 78.1 | 86.6 | 62.0 | 74.7 |
Cash conversion cycle (days) | -28.5 | -26.5 | -38.7 | -4.9 | -23.0 |
Net debt / EBITDA, incl. leases (x)
| Net debt / EBITDA, incl. leases (x) | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|
Net debt / EBITDA (x) | 10.6 | 10.9 | 3.3 | 4.7 |
Geographic revenue (ZAR Mn)
| Geographic revenue (ZAR Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
South Africa (ZAR Mn) | 117.4 | 162.2 | 177.0 | 229.5 | 219.1 |
Australia (ZAR Mn) | 289.2 | 319.4 | 299.3 | 451.2 | 445.7 |
Australia revenue in AUD at average rates (AUD Mn)
| Australia revenue in AUD at average rates (AUD Mn) | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Australia (AUD Mn) | 29.0 | 31.5 | 28.5 | 39.3 | 40.4 |
Revenue by type and geography, FY2022 (ZAR Mn)
| Revenue by type and geography, FY2022 (ZAR Mn) | South Africa | Australia | Total |
|---|---|---|---|
Facility fees | 129.9 | 425.1 | 555.0 |
Equipment and fixed fees | 13.3 | 0.6 | 13.9 |
Specialists | 0.0 | 11.4 | 11.4 |
Drugs and gases | 75.9 | 8.5 | 84.4 |
Total | 219.1 | 445.7 | 664.7 |
Share Price History
| Date | Price / value (ZAR cents) | Context | Source |
|---|---|---|---|
Apr 2014 | 100 | AltX listing issue price | [S31] |
Aug 2017 | 130 | Rights offer subscription price | [S26] |
18 Aug 2017 | 106 | Closing price amid an increased-loss trading update | [S28] |
Late 2020 | 18 (low) | Trough | [S31] |
Apr 2021 | 24 | Rights offer price | [S19], [S20] |
Nov 2022 | 25 | Before the PMA deal | [S31] |
Jun 2023 | 80 | Scheme consideration | [S11] |
Sep 2023 | 80 + 20 | Scheme plus clean-out dividend = 100c total exit | [S14], [S31] |
Share Count (millions) and Per-Share Data
| Capital data | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|
Shares in issue, year-end (millions) | 288.0 | 288.0 | 288.0 | 498.8 | 498.8 |
NAV per share, total equity incl. NCI (ZAR cents) | 85.9 | 72.9 | 53.6 | 36.0 | 46.7 |
NAV per share, attributable to owners (ZAR cents) | 67.3 | 50.6 | 13.4 | 8.9 | 3.8 |
Dividend per share (ZAR cents) | 0 | 0 | 0 | 0 | 0 |
Analyst Conclusions
Management guidance
There is no quantitative guidance. The last formal statement (April 2023) expected the remaining South African business to become profitable and to grow a footprint of independent, quality, cost-effective day hospitals [S5]. 2026 communications emphasise quality (ISO 7101) and three pillars (staff, patients, doctors) [S36].
Consensus
Not available (unlisted; no sell-side coverage).
Bull case
-
Lower fixed charges: PMA proceeds of about R522m were earmarked to settle credit facilities [S8]. Holding-company finance costs (R7.9m in H1 FY2023 [S5]) and EK interest could fall sharply, letting South African EBITDA (R17.3m in H1 FY2023) convert to profit.
-
Structural tailwinds: scheme steering, co-payments on acute use and member down-trading favour low-price day facilities [S5]. Day surgery was only 12–15% of South African private surgery in 2018, against much higher shares abroad [S29].
-
Differentiation and reach: ISO 7101 [S36], same-day joint replacement capability [S35] and Eastern Cape entry through MFT [S39] widen the procedure pool and strengthen the case for network inclusion.
Bear case
-
History of losses: South Africa lost R41–132m a year over five years and never reported an after-tax profit [S1]–[S4]. Even the FY2021 COVID backlog year produced a R47.7m South African loss.
-
Competitive pressure: Cure Day Hospitals (14 sites, including a 2026 opening in the same Gqeberha market) is out-scaling Advanced Health [S43]. The acute groups operate their own day facilities and are investing heavily from strong cash flows (Netcare capex R1.63bn in FY2025) [S40], [S42].
-
Opacity and funding concentration: no public financials since H1 FY2023, a single controlling funder, and leases that still weigh heavily on the remaining business, leave outsiders unable to verify any turnaround.
Catalysts and monitorables (next 12 months)
-
Any published annual financial statements (CIPC filings, PAIA disclosures) showing post-2023 profitability.
-
Constitutional Court rulings on the NHI process and any subsequent promulgation [S44].
-
2027 medical-scheme tariff outcomes negotiated through DHASA.
-
Network changes: new openings, acquisitions or doctor-equity sales.
-
ISO 7101 surveillance audits [S36].
-
MFT's competitive position after Cure's Gqeberha opening [S43].
-
Funder solvency events, given the 2026 curatorship that affected Life Healthcare [S42].
Analyst verdict
Advanced Health's listed life (2014–2023) is best read as an expensive experiment in building an independent South African day-hospital network inside a structure that could not fund it. The Australian subsidiary was the economic engine. It generated R62.5–62.6m of after-tax profit a year by FY2021–FY2022 [S4] and was finally monetised for about AUD45m [S8]. The South African build-out absorbed that value: South Africa lost money every year on record, the group carried going-concern emphasis paragraphs, and attributable book equity fell from R193.8m to R19.0m between FY2018 and FY2022 [S1], [S4]. Public shareholders who bought at the 100c listing price left with exactly 100c nine years later [S31].
The fundamental thesis behind the business was not wrong. Day surgery is cheaper, schemes increasingly favour it, and South Africa remains under-penetrated compared with developed markets [S29], [S5]. The failure was one of capital structure and scale. Leases and related-party debt consumed most of the EBITDA, and a sub-national footprint limited bargaining power with funders.
Today's Advanced Health is a smaller, single-country, founder-controlled operator of nine hospitals. It has better quality credentials (ISO 7101) and, assuming the PMA proceeds retired debt as stated, probably a lighter balance sheet. It also faces a better-scaled independent rival in Cure Day Hospitals and well-capitalised acute incumbents. Because the company publishes no financials, any claim that the turnaround has succeeded cannot be verified.
Verdict: for counterparties such as funders, suppliers, landlords and potential acquirers, Advanced Health should be treated as a credible but sub-scale niche operator with an unproven profit model. Diligence should focus on post-2023 audited accounts, the remaining lease commitments, surgeon retention and any continuing financial support from Eenhede Konsultante. For investors, there is no public instrument. The most plausible future events are consolidation (Advanced Health as either acquirer or target) or selective doctor-equity raises, rather than a return to the public market.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles / notes | Education / age | Source |
|---|---|---|---|---|---|
Carl Alfred Grillenberger | Founder; non-executive chairman (from 28 Aug 2019); previously CEO | Founder; CEO at listing (2014) and in 2018 | Founded PresMed (South Africa) in 1982 and PresMed Australia in 1997; associated with controlling shareholder Eenhede Konsultante | — | [S27], [S29], [S33], [S1], [S30] |
Gerhard (Gerhardus Jacobus) van Emmenis | Chief Executive Officer | From 1 Aug 2019; quoted as CEO in Aug 2023. Current status not confirmed by 2026 sources | — | — | [S1], [S31] |
D. (Bibi) Goss-Ross | Managing Director, Advanced Health Group (title used Feb 2026); previously MD South Africa and executive director | Alternate director to 1 Dec 2021, then director | Led the company through ISO 7101 certification | — | [S4], [S5], [S36] |
M. Stoltz | Interim CFO | From 1 Apr 2023 | — | — | [S5] |
Sinenhlanhla Chonco CA(SA) | CFO (former) | 1 Feb 2020 – 31 Mar 2023 | — | CA(SA) | [S2], [S5] |
Marna Castelyn | Acting CFO (former) | 1 Nov 2019 – Jan 2020 | — | — | [S2] |
Carel Petrus Snyman CA(SA) | CFO (former) | To 31 Oct 2019 | — | CA(SA) | [S1] |
Marc C. Resnik | MD / COO Australia (former executive director) | To the PMA sale (2023) | Exercised options for 76,672 PMA shares (4.13%) through Kinser Investments in FY2022 | Australian | [S4] |
Sr Anina de Bruyn | Group Clinical and Quality Manager | Current (2026) | Led the ISO 7101 project | — | [S36] |
M. Janse van Rensburg | Company Secretary | FY2019–FY2023 | — | — | [S1], [S5] |
“—” = not publicly disclosed.
Board of Directors
| Director | Role | Independence / notes | Source |
|---|---|---|---|
C.A. Grillenberger | Chairman, non-executive | Not independent (controlling-shareholder associate) | [S5] |
F.A. van Hoogstraten | Lead independent non-executive director; chairman until Aug 2019 | Independent | [S5], [S1] |
P.J. (Phil) Jaffe | Non-executive director | Independent; Independent Board member for the 2023 scheme; Australian | [S5], [S11] |
Dr W.T. (Tommy) Mthembu | Non-executive director | Independent; Independent Board member for the 2023 scheme | [S5], [S11] |
Y.J. (Cobus) Visser | Non-executive director (previously alternate) | Independent; Independent Board member for the 2023 scheme | [S5], [S11] |
C.J.P.G. van Zyl | Non-executive director | Independence not stated | [S5] |
Dr K.E. (Kgao) Legodi | Non-executive director (from 27 Nov 2019) | Independence not stated | [S2], [S5] |
G.J. van Emmenis | CEO, executive director | Executive | [S5] |
M.C. Resnik | MD Australia, executive director | Executive | [S5] |
D. Goss-Ross | MD South Africa, executive director | Executive | [S5] |
S. Chonco | CFO, executive director (to 31 Mar 2023) | Executive | [S5] |
Dr J. Oelofse | Former non-executive director | Term ended 12 Nov 2021 | [S4] |
Major Shareholders
| Shareholder | Shares | % of issued |
|---|---|---|
Eenhede Konsultante Eiendoms Beperk (offeror) | 287,495,276 | 57.64 |
Pres Medical Witbank (Pty) Ltd (excluded shareholder) | 53,190,440 | 10.66 |
John Biccard (irrevocable undertaking) | 12,831,384 | 2.57 |
Rendement (Pty) Ltd (irrevocable undertaking) | 12,800,000 | 2.57 |
Carl Grillenberger Family Trust (excluded shareholder) | 10,420,508 | 2.09 |
Bremer Investments (Pty) Ltd (irrevocable undertaking) | 6,497,500 | 1.30 |
VC Family Trust (excluded shareholder) | 3,661,259 | 0.73 |
Fiona Biccard (irrevocable undertaking) | 836,391 | 0.17 |
Offeror plus excluded shareholders (concert group) | 354,767,486 | 71.13 |
Competitive Landscape
Key Competitors
| Competitor | Type | Overlap with Advanced Health | Scale / financials | Source |
|---|---|---|---|---|
Netcare Ltd | Listed national acute group with day-surgery and eye facilities (e.g. Netcare Optiklin Eye Hospital) | Elective surgery volumes; network inclusion | FY2025 revenue R26,344m; normalised EBITDA R4,912m (18.6%) | [S40], [S95a] |
Life Healthcare Group | Listed national acute group with day hospitals (e.g. Life Brooklyn Day Hospital) | Same | FY2025 acute revenue R21.3bn (like-for-like); group normalised EBITDA R3.8bn | [S41], [S91a] |
Mediclinic Southern Africa | Acute group with day clinics (e.g. Bloemfontein, Limpopo, Nelspruit day clinics) | Same | — | [S91a] |
Cure Day Hospitals Holdings | Independent day-hospital chain (founded 2007 by doctors) | Most direct business-model competitor; overlaps in Gqeberha | 14 hospitals as of June 2026; financials not publicly disclosed | [S43], [S47] |
Intercare | Day hospitals (e.g. Irene) | Gauteng day surgery | — | [S91a] |
Melomed Hospital Holdings | Private hospital group, Western Cape | Western Cape elective surgery | — | [S48] |
National Hospital Network (NHN) | Network of independent hospitals | Funder contracting alternative for independents | — | [S48] |
Edge Day Hospital | Independent day hospital | Day surgery | — | [S48] |
Bay Eye Hospital | Independent ophthalmic hospital | Ophthalmology | — | [S48] |
Independent day hospitals (e.g. Medgate's network peers, Mercidoc, Birchmed, Karibu, Groenkloof) | Single-site independents | Local competition for surgeons | — | [S97a] |
“—” = not publicly disclosed.
Peer Comparison FY2025
| Metric | Advanced Health (FY2022, group) | Advanced Health (FY2022, South Africa only) | Netcare (FY2025) | Life Healthcare (FY2025) | Cure Day Hospitals |
|---|---|---|---|---|---|
Revenue | R664.7m | R219.1m | R26,344m | Acute R21.3bn (like-for-like) | — |
Revenue growth | -2.3% | -4.6% | 4.5% | Group 6.0% | — |
EBITDA margin | 20.2% | 12.5% | 18.6% (normalised) | — | — |
Facilities | 9 SA + 10 AU (FY2022) | 9–10 | National | National | 14 (Jun 2026) |
“—” = not publicly disclosed.



